ABT-263 (Navitoclax) 化学構造
分子量: 974.61

高品質保証

文献中の引用(36)

カスタマーフィードバック(13)

Quality Control & MSDS

製品説明

  • Compare Bcl-2 Inhibitors
    Bcl-2製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 ABT-263(Navitoclax)は、 Bcl-xLBcl-2Bcl-w の強力な阻害剤で、Kiがそれぞれ ≤ 0.5 nM、≤1 nM 、≤ 1 nMです。
ターゲット

Bcl-xL

Bcl-2

Bcl-w

IC50

≤ 0.5 nM (Ki)

≤1 nM (Ki)

≤ 1 nM (Ki)[1]

In vitro試験 ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cell NHzIUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn6cm5SUUN3ME2wMlAxPjZ7IN88US=> NGL6PZZUSU6JRWK=
MV-4-11 NYjFUWJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMEG1PFYh|ryP NFToT4ZUSU6JRWK=
NKM-1 NGTSUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVraNG5{UUN3ME2wMlAyPjl7IN88US=> NHH0eYtUSU6JRWK=
ML-2 NETWXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDKTpE{UUN3ME2wMlAyQTh|IN88US=> MkLFV2FPT0WU
BV-173 M2PE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\iNI5QUUN3ME2wMlAzOzF2IN88US=> NHT4epZUSU6JRWK=
RS4-11 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrzWVYyUUN3ME2wMlAzPTh5IN88US=> M1zyXnNCVkeHUh?=
HL-60 NUDPNYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXJTWM2OD1yLkCyPVA5KM7:TR?= MYTTRW5ITVJ?
KY821 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTFWFZKSzVyPUCuNFI6PzVizszN MoixV2FPT0WU
ECC10 MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLiTWM2OD1yLkCzO|kzKM7:TR?= MXHTRW5ITVJ?
NCI-H720 M4PLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTnTWM2OD1yLkC0NFEyKM7:TR?= MkmxV2FPT0WU
QIMR-WIL MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj6WY1mUUN3ME2wMlA1Ojh5IN88US=> NF7GPVFUSU6JRWK=
KG-1 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDZTWM2OD1yLkC0OFg3KM7:TR?= NYPuPIk1W0GQR1XS
TGW Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPrTWM2OD1yLkC0OlM{KM7:TR?= NWf6NG1jW0GQR1XS
ATN-1 NX7qUHN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrmTWM2OD1yLkC0O|M{KM7:TR?= MYrTRW5ITVJ?
RH-18 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvuTWM2OD1yLkC2NFQ5KM7:TR?= NI\mNnhUSU6JRWK=
EW-18 M4nBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLiTWM2OD1yLkC2PFQyKM7:TR?= NITac|lUSU6JRWK=
NB17 NHHqSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfkTWM2OD1yLkC3NVI1KM7:TR?= MXLTRW5ITVJ?
SK-NEP-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEeyNVMh|ryP MYDTRW5ITVJ?
P12-ICHIKAWA NWPlO|U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nSTGlEPTB;MD6wO|c4QCEQvF2= MWHTRW5ITVJ?
KARPAS-45 NHjmbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPDfVRDUUN3ME2wMlA4QDF3IN88US=> MmS1V2FPT0WU
EW-3 NFvFbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzqbVRKSzVyPUCuNFgxPTNizszN MkOwV2FPT0WU
NB13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfOW5BEUUN3ME2wMlA5OjB|IN88US=> M3XSVHNCVkeHUh?=
NCI-H209 NYr1R4JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXlTWM2OD1yLkC4O|A1KM7:TR?= MYXTRW5ITVJ?
NCI-H1092 NH;nVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr5TWM2OD1yLkGwNlc2KM7:TR?= NWXQXGhMW0GQR1XS
NH-12 MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHZdHdKSzVyPUCuNVA4PDRizszN M{TMOHNCVkeHUh?=
697 M4HOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPJOJRKUUN3ME2wMlExQDN7IN88US=> M1fGcXNCVkeHUh?=
KE-37 NVS2OXdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzTT|JKSzVyPUCuNVE{PyEQvF2= MYDTRW5ITVJ?
MOLT-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe1[|g6UUN3ME2wMlE2OTZ7IN88US=> NF7hdXFUSU6JRWK=
CHP-134 M2e3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HNSWlEPTB;MD6xOlMxPiEQvF2= M1K4UnNCVkeHUh?=
D-283MED MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfFTXhKSzVyPUCuNVc3QDZizszN NEj4O4ZUSU6JRWK=
LU-135 NH3l[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPZdHFKSzVyPUCuNVg2PTJizszN MnWzV2FPT0WU
LU-134-A M1\5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLUS5JpUUN3ME2wMlE5PjdzIN88US=> MkS5V2FPT0WU
EM-2 NHW3N2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjabmlXUUN3ME2wMlE6QTF6IN88US=> NF7JPFFUSU6JRWK=
LU-139 NVvxd|VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PrTmlEPTB;MD6yNFQ6QCEQvF2= M3PzUnNCVkeHUh?=
ALL-PO MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMkG5PFgh|ryP MVXTRW5ITVJ?
NB12 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LQfmlEPTB;MD6yN|EyPSEQvF2= MmXLV2FPT0WU
KP-N-YN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3Cd21KSzVyPUCuNlM2PzNizszN NGLDd2hUSU6JRWK=
BEN MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMkO5Olgh|ryP NFj1TG9USU6JRWK=
HCC1569 NGnzO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMkWxNFYh|ryP MYXTRW5ITVJ?
HuO9 NG\mUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDpUZVKSzVyPUCuNlY4OTVizszN MWrTRW5ITVJ?
WM-115 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i1PWlEPTB;MD6yO|c{QCEQvF2= NFvOV5BUSU6JRWK=
CCRF-CEM NVn6eHpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILmSVZKSzVyPUCuN|M2OjlizszN NIjXO2xUSU6JRWK=
IST-SL1 NXP3fG9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;EVWlEPTB;MD6zOVM1OyEQvF2= NUDEeJJCW0GQR1XS
BE-13 NHTFOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH6TWM2OD1yLkO2OFU6KM7:TR?= M3u0W3NCVkeHUh?=
COR-L88 M4jMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\hTXFKSzVyPUCuN|Y2PCEQvF2= NFLZdm1USU6JRWK=
DOHH-2 M3jrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLBTWM2OD1yLkSxNFI{KM7:TR?= NGfTWFdUSU6JRWK=
A704 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTOR3d5UUN3ME2wMlQzPjdizszN NG\hT4JUSU6JRWK=
KNS-81-FD NIfZOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M164OWlEPTB;MD60OFAyPyEQvF2= NHnzdotUSU6JRWK=
RPMI-8226 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHXd|FYUUN3ME2wMlQ2PjV{IN88US=> MnvLV2FPT0WU
TGBC24TKB M1jRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHiZnR[UUN3ME2wMlQ2Pzd6IN88US=> NIr2UIdUSU6JRWK=
NCI-H1304 M1HDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj0dpFKUUN3ME2wMlQ3OTV5IN88US=> MYnTRW5ITVJ?
MOLT-13 NVnhO|liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC1[JFKSzVyPUCuOFY3OTNizszN M{XkW3NCVkeHUh?=
EW-22 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwNE[2O|Eh|ryP NGfuO|BUSU6JRWK=
MS-1 M324Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwNE[5N|Mh|ryP M33UbHNCVkeHUh?=
RMG-I MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO1TWM2OD1yLkS5OFY1KM7:TR?= NU\CW|ZqW0GQR1XS
NTERA-S-cl-D1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;TSJNKSzVyPUCuOVAxOTlizszN M3H3dnNCVkeHUh?=
NCI-H1048 NFfHcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;iTWM2OD1yLkWwPVU{KM7:TR?= MlmyV2FPT0WU
SW1417 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrtXWZzUUN3ME2wMlU2PDN6IN88US=> MW\TRW5ITVJ?
DB NWHQSYh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLETWM2OD1yLkW3NFgh|ryP NGXiRoJUSU6JRWK=
MEG-01 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HEOmlEPTB;MD61PFMzKM7:TR?= NUC2RZA3W0GQR1XS
EW-13 M3:2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXI[3AzUUN3ME2wMlU5OzRzIN88US=> NILsSlBUSU6JRWK=
LAMA-84 M1fiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwNUmyNFch|ryP MWfTRW5ITVJ?
J-RT3-T3-5 NULQXo1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DNS2lEPTB;MD62NFgxQCEQvF2= NHXpZYhUSU6JRWK=
MOLT-16 NWHKTYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\CRllKSzVyPUCuOlUzPjRizszN M1zsbHNCVkeHUh?=
DU-4475 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\wTWM2OD1yLk[1OFI4KM7:TR?= M1H5fXNCVkeHUh?=
HAL-01 NXjhenN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTF[2YyUUN3ME2wMlczPTR7IN88US=> NXXqRWpTW0GQR1XS
RD M4\2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLNUW5UUUN3ME2wMlc2QDl7IN88US=> MVzTRW5ITVJ?
OAW-28 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjhPGJKSzVyPUCuO|g{PyEQvF2= NXPB[IoxW0GQR1XS
HCC38 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrs[3VjUUN3ME2wMlgxOTlizszN NEHPPVFUSU6JRWK=
NMC-G1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK5RYlKSzVyPUCuPFEyOjFizszN NXTTVYl6W0GQR1XS
EW-16 NXzSUWtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LFN2lEPTB;MD64NVMzQCEQvF2= NHjp[2tUSU6JRWK=
DU-145 Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHETWM2OD1yLki5PVI{KM7:TR?= NX:3UopqW0GQR1XS
HPAF-II M1L0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXpVXFKSzVyPUCuPVI3OjhizszN NHi3bIVUSU6JRWK=
A427 NIC4d4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\MdmlEPTB;MD65N|AzOiEQvF2= Ml\QV2FPT0WU
PA-1 M1T0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwOUW2OFIh|ryP NXHHUYpnW0GQR1XS
OAW-42 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHuTWM2OD1yLkm2NVQ3KM7:TR?= NEGwNI1USU6JRWK=
L-428 NV75SJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlflTWM2OD1zLkCxNlUh|ryP MoHJV2FPT0WU
COLO-824 M4Pabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;r[GlEPTB;MT6wNVcxQCEQvF2= Mn\pV2FPT0WU
P30-OHK NWfQXHFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwMES2PFgh|ryP MnW1V2FPT0WU
NCI-H2170 NE[5PZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\LTWM2OD1zLkC2NlMh|ryP MUTTRW5ITVJ?
HCC2998 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnFWoFKSzVyPUGuNFcyOzVizszN M4Gxb3NCVkeHUh?=
NB14 NX3qUYNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjTblJKSzVyPUGuNVM4PDhizszN M3X5V3NCVkeHUh?=
TGBC1TKB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT5XohEUUN3ME2xMlE1OTV{IN88US=> M4OxT3NCVkeHUh?=
KP-N-YS NWHTepBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWwcG1EUUN3ME2xMlE3OjN4IN88US=> Moj2V2FPT0WU
CAL-120 NGjGcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LqfWlEPTB;MT6xOlQzQSEQvF2= NGXScVRUSU6JRWK=
SBC-1 NI[3VI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTtTHBGUUN3ME2xMlE6ODV|IN88US=> NVraOG1xW0GQR1XS
C32 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjCfYJKSzVyPUGuNVkxQDhizszN NFX2OZVUSU6JRWK=
HCC2157 Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDN[GcxUUN3ME2xMlE6PDl2IN88US=> M37vUnNCVkeHUh?=
COLO-792 NIDae|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S0d2lEPTB;MT6yNFA4OSEQvF2= MXvTRW5ITVJ?
ES7 NYXEfW1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwMke5OVEh|ryP MkTEV2FPT0WU
HEL NYH5OGtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7nTWM2OD1zLkOxNFI6KM7:TR?= M37ZOHNCVkeHUh?=
ES4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDnNYd7UUN3ME2xMlM1QTl6IN88US=> M2LmdHNCVkeHUh?=
NCI-SNU-1 M{i3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwM{[1OVUh|ryP MlfSV2FPT0WU
MDA-MB-415 NFzvfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XldWlEPTB;MT6zPFg2KM7:TR?= MmjnV2FPT0WU
NCI-H2342 NYXpWGVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwNECyOlkh|ryP M{jDWHNCVkeHUh?=
NB69 NXvXZWJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj2TnRtUUN3ME2xMlQ3OjdzIN88US=> M2PzOnNCVkeHUh?=
D-247MG M4K3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[wbZd4UUN3ME2xMlUyOTJ{IN88US=> MnrxV2FPT0WU
SCC-4 M2\iW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwNUm4PFch|ryP NF\mZVdUSU6JRWK=
HuH-7 NV:2V3R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFwNkeyPVMh|ryP MYLTRW5ITVJ?
A388 M{HxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULKfY5KUUN3ME2xMlY5PzJ2IN88US=> MlP4V2FPT0WU
Calu-3 NWDTfWJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\3b3ZlUUN3ME2xMlcxPjl5IN88US=> NFfyOGhUSU6JRWK=
NCI-H1648 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPuNllKSzVyPUGuO|E1OThizszN NWDBT5h1W0GQR1XS
NCI-H2052 NWfLdWl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq1TWM2OD1zLkeyNlAyKM7:TR?= MW\TRW5ITVJ?
Ramos-2G6-4C10 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvwcWRKSzVyPUGuO|M3PTZizszN MXXTRW5ITVJ?
DEL MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXIXndKSzVyPUGuO|Q3QTJizszN NHXoNZlUSU6JRWK=
SNU-423 NY\LVnRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[yWmZKSzVyPUGuO|gyPTdizszN NYK0NmdxW0GQR1XS
COR-L23 NFzyRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwN{m4O|Qh|ryP MV3TRW5ITVJ?
OMC-1 NXzjU29jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjkOnlnUUN3ME2xMlg3ODF4IN88US=> MVPTRW5ITVJ?
EW-11 M2raVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fITmlEPTB;MT65OVY2PyEQvF2= NViwdVJQW0GQR1XS
HSC-3 M1fWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP5TWM2OD1zLkm2N|Y2KM7:TR?= M{DnTHNCVkeHUh?=
MLMA MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwOU[2O|ch|ryP M3WyT3NCVkeHUh?=
RCM-1 M37JXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PyfmlEPTB;Mj6wNFM6QSEQvF2= NGPZSW1USU6JRWK=
MFE-280 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHBTWM2OD1{LkCyPFQ5KM7:TR?= NIOwfmpUSU6JRWK=
ES8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTsW3JKSzVyPUKuNlU1PzFizszN NWHKWWI6W0GQR1XS
TE-11 NWTlVJE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrPRnNKSzVyPUKuNlk1PzNizszN NVnjdoRvW0GQR1XS
HuO-3N1 NXrkXWhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD5fWU{UUN3ME2yMlQ5PzhizszN NXX3N4R1W0GQR1XS
MHH-NB-11 M2LVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljtTWM2OD1{LkWxNVU5KM7:TR?= NXHselJ3W0GQR1XS
TGBC11TKB NEjibXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\tOW1vUUN3ME2yMlU4PjhzIN88US=> NEjseGtUSU6JRWK=
HOP-92 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJwNUi3OFMh|ryP NGnu[YVUSU6JRWK=
IGR-1 NHLxe2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwNkKwN|Uh|ryP MkL2V2FPT0WU
GOTO NHLmNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu1cIRiUUN3ME2yMlY2Ozd5IN88US=> NFjoeVZUSU6JRWK=
NCI-H1650 NUfqR3d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfMZWZiUUN3ME2yMlczOjF3IN88US=> MWfTRW5ITVJ?
NCI-H1581 M{jnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJwN{m2PFEh|ryP NIL1OlZUSU6JRWK=
NCI-H2405 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\3TWM2OD1{LkiyO|gzKM7:TR?= MlHuV2FPT0WU
U-118-MG MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJwOU[0PVEh|ryP M1LCSnNCVkeHUh?=
DoTc2-4510 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTiTWM2OD1|LkCxOFE4KM7:TR?= M4HvNnNCVkeHUh?=
NCI-H596 NIrsXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTNwMES5PVch|ryP MmrEV2FPT0WU
MPP-89 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNwMEW2OlYh|ryP MlnQV2FPT0WU
GCIY MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jJRmlEPTB;Mz6yNFQ6OSEQvF2= NX3ZVWpqW0GQR1XS
SW626 NF;BN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP0TWM2OD1|LkK0OVQ{KM7:TR?= MX7TRW5ITVJ?
OCI-AML2 NUDBXotwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPxXW84UUN3ME2zMlMyOjd{IN88US=> M1PkXHNCVkeHUh?=
NBsusSR M2DvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGzTWM2OD1|LkO0PVM5KM7:TR?= NWS2bnRuW0GQR1XS
AN3-CA M1PRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrGZ4lKSzVyPUOuOFQzOzhizszN Mo\LV2FPT0WU
EFM-19 M1u4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOxTWM2OD1|LkS4N|M6KM7:TR?= NXrEd2l{W0GQR1XS
RVH-421 NF;OcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jSTGlEPTB;Mz61Olg4PyEQvF2= MWLTRW5ITVJ?
5637 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zPWGlEPTB;Mz62NVExOyEQvF2= M{S0RXNCVkeHUh?=
PANC-08-13 NWnHSYRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nl[GlEPTB;Mz62N|Q4OiEQvF2= MXrTRW5ITVJ?
H9 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTNwNkexOFQh|ryP MUPTRW5ITVJ?
KARPAS-299 MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrKO3Z2UUN3ME2zMlY4OzZzIN88US=> MojTV2FPT0WU
TE-5 NFjONHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml71TWM2OD1|LkewO|A6KM7:TR?= NVf3XlA2W0GQR1XS
NOS-1 NXHxNplsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwN{m4N|Qh|ryP NFG2fJdUSU6JRWK=
HH M1XKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTJfnNjUUN3ME2zMlg{QDZ6IN88US=> Ml;tV2FPT0WU
769-P NFzxTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KzcGlEPTB;Mz64PVUyKM7:TR?= MWnTRW5ITVJ?
CHP-212 MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH3bHFlUUN3ME2zMlkzPTR7IN88US=> NYHEPXFjW0GQR1XS
NCI-H82 MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPhcGFKUUN3ME2zMlk2QTN4IN88US=> M3nMWHNCVkeHUh?=
Mo-T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rKSWlEPTB;ND6wOFMyOiEQvF2= NGO5XJVUSU6JRWK=
BB65-RCC M3;RZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITCWmJKSzVyPUSuNFQ{QTlizszN NX3ScItnW0GQR1XS
SW1990 MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDNTJExUUN3ME20MlA2QTB6IN88US=> NXzzNYZ{W0GQR1XS
LK-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULnZ4hXUUN3ME20MlEyOjl|IN88US=> MXXTRW5ITVJ?
ES5 NWrF[FJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;5NmlEPTB;ND6xN|k5PSEQvF2= NUe4Xm1mW0GQR1XS
JVM-3 MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;yTWM2OD12LkG4NlIzKM7:TR?= NHHGTHhUSU6JRWK=
RPMI-7951 NVHoRYtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fKbmlEPTB;ND6yNlQyOyEQvF2= NXyzVnVjW0GQR1XS
Calu-6 MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqxTndKSzVyPUSuNlc5QDFizszN MWDTRW5ITVJ?
LC-2-ad MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;wXVlxUUN3ME20MlI6PTZ6IN88US=> MX;TRW5ITVJ?
SW954 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\CTWM2OD12LkK5OlYh|ryP M3HCPXNCVkeHUh?=
H-EMC-SS M13WPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTRwM{G4N|Eh|ryP M2fDZ3NCVkeHUh?=
ES3 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnZT2N7UUN3ME20MlM2PDRzIN88US=> MljVV2FPT0WU
no-11 NXT4S3JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\xTWM2OD12LkO1OVU1KM7:TR?= MlTzV2FPT0WU
LAN-6 NVP5N|YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHaTWM2OD12LkS1NVg6KM7:TR?= NHnRSJJUSU6JRWK=
FTC-133 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknpTWM2OD12LkWzPVUh|ryP MoPHV2FPT0WU
8505C NXXTR4V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuwRoNNUUN3ME20MlU1OjNizszN MYLTRW5ITVJ?
SW620 NWjuT5JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRwNUewOVch|ryP NVyyOpRUW0GQR1XS
BCPAP M{frb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33MWWlEPTB;ND62N|Q5OSEQvF2= MYLTRW5ITVJ?
SK-LU-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTRwNk[wPFkh|ryP MonMV2FPT0WU
NCI-H1623 NV62ZY5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LJVmlEPTB;ND63NFIzQCEQvF2= M3q1OXNCVkeHUh?=
C2BBe1 NGL4UpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fkSGlEPTB;ND63OFAxQCEQvF2= NHzCVI5USU6JRWK=
GP5d M3:zUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;XXmlEPTB;ND63PFM5QCEQvF2= M2r4bXNCVkeHUh?=
NB6 MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXCTWM2OD12Lki2NlA1KM7:TR?= Mm[4V2FPT0WU
MDA-MB-157 NXTCV4s{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LpOGlEPTB;ND64PFc3KM7:TR?= M1\tXXNCVkeHUh?=
UMC-11 NWLnNFJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTRwOEi5OlQh|ryP NH2zN2FUSU6JRWK=
HCC1419 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fZNmlEPTB;ND65NFA3OyEQvF2= MmK2V2FPT0WU
NCI-H2029 M4DTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOwbY5KSzVyPUSuPVQyQDVizszN M3fpenNCVkeHUh?=
LXF-289 NWXwWWRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTVwMEO3NVkh|ryP M{fBVHNCVkeHUh?=
KINGS-1 NYn6RWdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPjTWM2OD13LkC3O|Q1KM7:TR?= M3ryZnNCVkeHUh?=
HD-MY-Z NILReHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;CTWM2OD13LkKzPVY6KM7:TR?= Mkn1V2FPT0WU
ESS-1 NHPIWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTVwMkW1PVch|ryP NEDTfolUSU6JRWK=
GI-1 M3LYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC4TWM2OD13LkK3PVI3KM7:TR?= NX\KPW5FW0GQR1XS
RPMI-2650 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[3TWM2OD13LkO2NVYh|ryP M4\DZnNCVkeHUh?=
IA-LM NFPQb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;yZWZ{UUN3ME21MlM6QDdzIN88US=> M17UNnNCVkeHUh?=
KP-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO0O2dVUUN3ME21MlQ3OzN2IN88US=> Mor6V2FPT0WU
G-402 NEDHboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPwV5hKSzVyPUWuOVE5PjVizszN MXnTRW5ITVJ?
OS-RC-2 NYm0SlNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HRUmlEPTB;NT61NlYxPCEQvF2= MVHTRW5ITVJ?
NCI-H1155 NYPVfnByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTVwNUS5OVUh|ryP M4PMNnNCVkeHUh?=
OE19 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS0[3hKSzVyPUWuOlg3OjRizszN MYTTRW5ITVJ?
U-2-OS NHO2e29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqzWGxKSzVyPUWuPFkxOTNizszN NFPWVI9USU6JRWK=
SCC-15 NHjRS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTVwOUO2OlIh|ryP M2XJUXNCVkeHUh?=
NCI-H630 M2TMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTVwOUm0NFQh|ryP MlHKV2FPT0WU
PFSK-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTZwMEWyOVkh|ryP NETpfHVUSU6JRWK=
NCI-H1770 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi0dWFKSzVyPU[uNlA5PzRizszN NGHTOYlUSU6JRWK=
SK-MEL-3 MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTZwNEK5NVUh|ryP NYK4UG44W0GQR1XS
LB1047-RCC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[3VGdKSzVyPU[uOFc3OjVizszN Mn;kV2FPT0WU
NCI-H446 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj0TWM2OD14Lk[yPVI2KM7:TR?= NETyOJVUSU6JRWK=
SW780 NXnwTXBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny5TWM2OD14LkewNVg2KM7:TR?= MmDCV2FPT0WU
NEC8 NYjTe4w4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OzfWlEPTB;Nj63OlY{KM7:TR?= NV;Ib|BCW0GQR1XS
NOMO-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLoc3Q6UUN3ME22Mlc5OTFzIN88US=> M2Loc3NCVkeHUh?=
COLO-668 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHlTWM2OD14Lki0N|g4KM7:TR?= NVPtUJo3W0GQR1XS
MC116 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPy[G9KSzVyPU[uPVM5QTdizszN M3\xSXNCVkeHUh?=
HCC1937 NF[yPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfHTWM2OD14Lkm5NlUyKM7:TR?= NHL3VYZUSU6JRWK=
NCI-N87 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTdwMUmyPVMh|ryP MlTnV2FPT0WU
COLO-320-HSR NF3TXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTdwMkK3N|gh|ryP NUDWblV6W0GQR1XS
HCC1806 NU\GflNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTdwMk[wOFQh|ryP M4L0cHNCVkeHUh?=
OVCAR-3 NWPIc2FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBTWM2OD15LkOzNFM5KM7:TR?= MXXTRW5ITVJ?
NUGC-3 NELwZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fDUmlEPTB;Nz6zPVY6PCEQvF2= NU\RbGVNW0GQR1XS
SW1783 NUnMR2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvZSWFKSzVyPUeuOFMyPzVizszN MlfHV2FPT0WU
GCT MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiwV25KSzVyPUeuOVY6ODZizszN MXrTRW5ITVJ?
NCI-H2126 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTdwN{O2NlUh|ryP M13oXHNCVkeHUh?=
MEL-HO Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrLW4pEUUN3ME23Mlc4ODV2IN88US=> MX3TRW5ITVJ?
CAPAN-1 MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rHbmlEPTB;Nz63O|M2PyEQvF2= MlexV2FPT0WU
SW756 M3nYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTdwN{izN|Mh|ryP MYfTRW5ITVJ?
SKG-IIIa MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OyXGlEPTB;Nz64NVg6OiEQvF2= NFHxPYJUSU6JRWK=
HCE-T M3rkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfmNlFKSzVyPUeuPFc4QDNizszN NXPBZnlmW0GQR1XS
Ca-Ski M3zyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDKTWM2OD15Lkm5N|g{KM7:TR?= NFHKPXpUSU6JRWK=
COLO-684 NVW1Tm13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XPe2lEPTB;OD6wNVgyQCEQvF2= NFfkUVhUSU6JRWK=
KYSE-70 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi0OmZKSzVyPUiuNFc4OjlizszN NXTBR5pjW0GQR1XS
TI-73 NF;VTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\iTWM2OD16LkK1PFUyKM7:TR?= MY\TRW5ITVJ?
BT-20 NYfzcnZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRThwMk[wOVIh|ryP NF3sfnBUSU6JRWK=
MHH-ES-1 M3Lm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFexVlFKSzVyPUiuOVE5OzRizszN MlPpV2FPT0WU
TE-12 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13VSGlEPTB;OD61PVk{OSEQvF2= NVvkfVhnW0GQR1XS
YH-13 NFLXb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf0XWVKSzVyPUiuOlExODhizszN MYnTRW5ITVJ?
SF126 M1TrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRThwOEO4OlUh|ryP M3\lbnNCVkeHUh?=
J82 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;GdJZKSzVyPUiuPVAxOzhizszN NXj5SGVJW0GQR1XS
RCC10RGB MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLnb5BsUUN3ME24Mlk6PTZzIN88US=> MUPTRW5ITVJ?
SK-UT-1 NWfOO|FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLFfodtUUN3ME25MlA1QTR3IN88US=> MonHV2FPT0WU
LB2241-RCC MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDUTWM2OD17LkG5NVM4KM7:TR?= NUnOSGFbW0GQR1XS
LB996-RCC NIjKWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK1TWhKSzVyPUmuNVk5QSEQvF2= NFS4S4RUSU6JRWK=
EPLC-272H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDWd49UUUN3ME25MlM4PjV5IN88US=> NWDGTmptW0GQR1XS
CTV-1 M3;wbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe4TWM2OD17LkW2OVMzKM7:TR?= NYrZUoxPW0GQR1XS
HSC-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ToU2lEPTB;OT61O|U2KM7:TR?= NWPmPGx1W0GQR1XS
SK-MEL-28 NUHnfZJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTlwNkG4PVMh|ryP M1S3OXNCVkeHUh?=
MMAC-SF M3\pS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPkXpZKSzVyPUmuOlg4PSEQvF2= NXfWVIhyW0GQR1XS
CP50-MEL-B NX3TTndbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;3ZopKSzVyPUmuO|U4QDJizszN M4jCVnNCVkeHUh?=
HT-1080 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTlwN{e3N|kh|ryP M1v3RnNCVkeHUh?=
HEC-1 NXP5T3dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fRVmlEPTB;MUCuN|M2OiEQvF2= M4XHd3NCVkeHUh?=
AGS MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;3b5hHUUN3ME2xNE4{PzRizszN MXPTRW5ITVJ?
GAMG MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFyLkWxOlIh|ryP MYjTRW5ITVJ?
SW48 M{\k[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFyLkWxPFkh|ryP M2HkNXNCVkeHUh?=
U031 M{LEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor2TWM2OD1zMD61PVA5KM7:TR?= MXTTRW5ITVJ?
OVCAR-5 NELQcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW3O2JwUUN3ME2xNE43PDJ7IN88US=> NVm0eFNEW0GQR1XS
SF295 NV3J[Hc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fscGlEPTB;MUCuOlcxPCEQvF2= MoHXV2FPT0WU
BHT-101 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnPbI5KSzVyPUGwMlcyPzdizszN MUHTRW5ITVJ?
VMRC-RCZ MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFzLkOyNFEh|ryP M2ntUHNCVkeHUh?=
ACHN MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLKXoJjUUN3ME2xNU41OjFzIN88US=> M1P0[nNCVkeHUh?=
NCI-H526 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS4b3JKSzVyPUGxMlUxPDNizszN M{f5PHNCVkeHUh?=
MN-60 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHMd2tFUUN3ME2xNU42OzlizszN MVzTRW5ITVJ?
NCI-H2291 NG\rW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzkTWM2OD1zMT61OFY3KM7:TR?= MlvzV2FPT0WU
SCC-25 MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DaS2lEPTB;MUGuO|U2PiEQvF2= NH\0b5pUSU6JRWK=
SK-MEL-2 NFrOTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;I[25bUUN3ME2xNU44PjN5IN88US=> NIrNUpJUSU6JRWK=
SN12C NXPncW5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq1THNjUUN3ME2xNU46OzV3IN88US=> MmT5V2FPT0WU
NCI-H69 MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojuTWM2OD1zMj60NlM1KM7:TR?= M{\TfHNCVkeHUh?=
ME-180 MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDhVlFKSzVyPUGyMlcxPTRizszN MmfuV2FPT0WU
MC-IXC NWPodGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTmSFFIUUN3ME2xNk44PTF6IN88US=> M37CRnNCVkeHUh?=
NCI-H2347 M2iwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF{Lke2NVQh|ryP NFTx[3ZUSU6JRWK=
M059J NWewbVFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF{Lke3Nlch|ryP M{fTc3NCVkeHUh?=
A2058 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly2TWM2OD1zMj64OlgyKM7:TR?= MYHTRW5ITVJ?
VA-ES-BJ Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv3N|BKSzVyPUGyMlg4QDVizszN NYSxdII2W0GQR1XS
Ca9-22 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHLU3ZKSzVyPUGyMlk1PTFizszN NWmzb4I1W0GQR1XS
KNS-42 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rZ[mlEPTB;MUKuPVk5PCEQvF2= MX;TRW5ITVJ?
LoVo MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF|LkKzNVMh|ryP MWDTRW5ITVJ?
AM-38 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF|LkK1OlYh|ryP M1rvb3NCVkeHUh?=
NB5 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGCzPFZKSzVyPUGzMlM4PTJizszN NFe0eGFUSU6JRWK=
L-363 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG1SopKSzVyPUGzMlQxOzNizszN MmLZV2FPT0WU
SK-MEL-30 NUO1N4JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj4TWM2OD1zND6wOlQ2KM7:TR?= MljkV2FPT0WU
NCI-H1563 NGDYPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF2Lk[wN|kh|ryP NYfYfY1pW0GQR1XS
NCI-H2228 M4X3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT6TWM2OD1zND62NFc4KM7:TR?= MX3TRW5ITVJ?
MFM-223 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS4TWFKSzVyPUG1MlE5OTNizszN NGXKe4FUSU6JRWK=
LB831-BLC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[1R4Y1UUN3ME2xOU4zPzZ5IN88US=> MVjTRW5ITVJ?
SW872 NEnL[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPDTWM2OD1zNT6zNFg3KM7:TR?= MUjTRW5ITVJ?
NCI-H522 NUfVWYY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv2U5A3UUN3ME2xOU4{OzB4IN88US=> M1;WdXNCVkeHUh?=
EW-1 NYXXfHg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnKVnJZUUN3ME2xOU42PDZ{IN88US=> NHnXT5pUSU6JRWK=
HN NH;1Zm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfqUXZKSzVyPUG1MlU6PDJizszN MULTRW5ITVJ?
SW837 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLqOFBKSzVyPUG1Mlc5PDdizszN NF\BT2RUSU6JRWK=
SCC-9 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF3LkixNVQh|ryP NGHqO2dUSU6JRWK=
MKN7 NFLXVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DGUmlEPTB;MUWuPVc{OiEQvF2= NIDDfnVUSU6JRWK=
KYSE-410 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF4LkW5NUDPxE1? NXH6SY1QW0GQR1XS
SK-N-DZ M3TifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHTN29KSzVyPUG2MlYyOTZizszN NV2yU4REW0GQR1XS
COR-L105 M{LMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;DUYtVUUN3ME2xOk43PTJ6IN88US=> MkK5V2FPT0WU
LB2518-MEL MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq3UJJKSzVyPUG2Mlg{QDlizszN Ml3vV2FPT0WU
OVCAR-4 MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTvTWM2OD1zNj64PFYzKM7:TR?= M4\xWHNCVkeHUh?=
TK10 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF4Lkm0O|Mh|ryP MlvPV2FPT0WU
KNS-62 NIXEdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DyfmlEPTB;MU[uPVc4PyEQvF2= MUTTRW5ITVJ?
RPMI-8866 M3vmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nZb2lEPTB;MUeuNVc{OiEQvF2= MYDTRW5ITVJ?
HuP-T4 MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF5LkK0PVUh|ryP NIHGNmZUSU6JRWK=
CGTH-W-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvjb5BKSzVyPUG3MlUzOTlizszN MVPTRW5ITVJ?
T-24 NHL6OGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF5LkWzOFch|ryP MXrTRW5ITVJ?
HT-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXoTWM2OD1zNz61PVE1KM7:TR?= M4nX[nNCVkeHUh?=
KS-1 M3jSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF5Lk[3N{DPxE1? NYLpbYFlW0GQR1XS
NCI-H1792 NH3OT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe5TWM2OD1zNz63PVgh|ryP M{nBRnNCVkeHUh?=
ABC-1 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvOS49KSzVyPUG3MlgyPDFizszN NXPzcJRUW0GQR1XS
BPH-1 NE\xdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP2TWM2OD1zOD6xOlg2KM7:TR?= MonQV2FPT0WU
A431 NGTwU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljVTWM2OD1zOD60NVI4KM7:TR?= NEDtUY5USU6JRWK=
T98G M{\RVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjGTWM2OD1zOD61NVU4KM7:TR?= NIDobVRUSU6JRWK=
BHY MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjQdZhKSzVyPUG4Mlg3QSEQvF2= MWLTRW5ITVJ?
Capan-2 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF6LkmwO|gh|ryP Mkm4V2FPT0WU
MDA-MB-175-VII MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;oT2h1UUN3ME2xPE46OjB7IN88US=> NHPmTGlUSU6JRWK=
CAL-27 NG[4OXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXjZ4RQUUN3ME2xPU4xPDh5IN88US=> M13zbXNCVkeHUh?=
AsPC-1 NGSzWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfHTWM2OD1zOT64OlU4KM7:TR?= Ml;0V2FPT0WU
KU812 M3;tOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF7Lkm1O|Mh|ryP NUGxWFFUW0GQR1XS
NCI-H441 NFHNPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJyLkCwNUDPxE1? NF;xeGtUSU6JRWK=
Mewo MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf4THJKSzVyPUKwMlEzQDhizszN MnL6V2FPT0WU
SK-MEL-24 M3XQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJyLkG0O|ch|ryP MkjmV2FPT0WU
NCI-H727 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHQTWM2OD1{MD6yO|A1KM7:TR?= MoXkV2FPT0WU
EKVX NEDDd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\SeGlEPTB;MkCuOlA3KM7:TR?= MXvTRW5ITVJ?
RT-112 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJyLk[xNlIh|ryP MX3TRW5ITVJ?
CAMA-1 NFPSXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJyLkm4NFMh|ryP NVjoRo5[W0GQR1XS
SW900 NYH4e5Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnWTWM2OD1{MT6wNVQ6KM7:TR?= NHXnXo9USU6JRWK=
NCI-H23 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJzLkGyO|ch|ryP MXXTRW5ITVJ?
SK-PN-DW NYXsW41{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ucWlEPTB;MkGuNVY1QSEQvF2= NHrKWI5USU6JRWK=
BB30-HNC MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXoTWM2OD1{MT6yO|Q2KM7:TR?= MVzTRW5ITVJ?
VM-CUB-1 NFfuWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTNTWM2OD1{MT6zOVM3KM7:TR?= Ml2xV2FPT0WU
IST-MEL1 NWDK[m86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJzLkO2PVIh|ryP M3q0OnNCVkeHUh?=
CTB-1 NVj1OWtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJzLkS3OVUh|ryP MlP1V2FPT0WU
LCLC-103H NHfnTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme3TWM2OD1{Mj6xOVgzKM7:TR?= NU\pOWM3W0GQR1XS
PANC-03-27 NF\Ed2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\zcmlEPTB;MkKuOVE3QSEQvF2= M{HwPHNCVkeHUh?=
HTC-C3 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ{LkW1OVUh|ryP M{ToO3NCVkeHUh?=
TE-8 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjkXpBEUUN3ME2yN{4zPTZ3IN88US=> M3zrT3NCVkeHUh?=
NCI-H292 NVPVeW06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH25fW9KSzVyPUK1MlM2OzZizszN NFHOS41USU6JRWK=
COLO-680N MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36xTWlEPTB;MkWuOlMzQSEQvF2= MXLTRW5ITVJ?
KYSE-520 NXnKfWtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ3Lk[0OEDPxE1? MlrKV2FPT0WU
NB10 NUH1Rm95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnRd4dKSzVyPUK2MlMyOTdizszN NYHFT3dlW0GQR1XS
NCI-H661 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ToUGlEPTB;Mk[uOFcyOyEQvF2= NIHsVYxUSU6JRWK=
GMS-10 M{fnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ4Lki2N|gh|ryP NGPXcJRUSU6JRWK=
NCI-H2122 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1SwOGlEPTB;Mk[uPVk6QCEQvF2= M1GwSXNCVkeHUh?=
OVCAR-8 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr5TWM2OD1{Nz6wOlM5KM7:TR?= NGCzdndUSU6JRWK=
DJM-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrueGNKSzVyPUK3MlE1PTRizszN NH;6S3NUSU6JRWK=
UACC-893 MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjBTWM2OD1{Nz65PFc5KM7:TR?= NF7ONXBUSU6JRWK=
C8166 M2HPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HqPWlEPTB;MkiuOlk{QCEQvF2= M1PTcHNCVkeHUh?=
NCI-H1693 Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXUbFR2UUN3ME2yPE43QTd3IN88US=> NXraXopEW0GQR1XS
TYK-nu M1[wfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLUeHZKSzVyPUOwMlA{PDVizszN NEK2UGlUSU6JRWK=
SW1710 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjiT2xKSzVyPUOwMlEzPiEQvF2= MVvTRW5ITVJ?
A375 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTNyLkOyOFMh|ryP MVjTRW5ITVJ?
HMV-II M12xTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHlW|RKSzVyPUOxMlM2QTJizszN NInwOXNUSU6JRWK=
NCI-H2087 M1Lr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTNzLk[zOVIh|ryP M1zCTnNCVkeHUh?=
CAL-54 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fnVGlEPTB;M{GuO|I1OSEQvF2= MYLTRW5ITVJ?
HCC70 MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP1fYxWUUN3ME2zNk4yOzh5IN88US=> NXznU4I5W0GQR1XS
ES1 NYm5bGhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTN{LkOwOlIh|ryP M4PIOnNCVkeHUh?=
NCI-H1355 NGn4cFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjvNoRSUUN3ME2zN{4zODRizszN NIGwe4tUSU6JRWK=
CFPAC-1 NGDKeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrZRnNKSzVyPUOzMlI{OzJizszN NV\XXYF5W0GQR1XS
MKN28 M13RUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq5TWM2OD1|Mz6zPFA6KM7:TR?= Mm[1V2FPT0WU
HDLM-2 NEDj[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\5ZWFKSzVyPUOzMlY6OzFizszN NF63[INUSU6JRWK=
PANC-10-05 NYO2enIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTN2LkGwNVQh|ryP NFnyR5JUSU6JRWK=
SAS Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHKTWM2OD1|ND60OVY2KM7:TR?= M1XkSHNCVkeHUh?=
HCC1395 NFLW[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LERWlEPTB;M{SuO|E5PiEQvF2= MkHXV2FPT0WU
8305C NHPxfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvQWWZiUUN3ME2zOU45PDF3IN88US=> NWLBfm5OW0GQR1XS
KM12 M3vnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf5NVJKSzVyPUO2Mlc2PDdizszN MYHTRW5ITVJ?
SW1116 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO5TWM2OD1|Nz61PVkzKM7:TR?= M3\1N3NCVkeHUh?=
SK-MEL-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTN6LkOzPFkh|ryP NUjQdZZnW0GQR1XS
HCC2218 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G0cWlEPTB;M{iuOlUyQSEQvF2= NFexU2VUSU6JRWK=
T84 Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTN6Lke0NFkh|ryP NXi5RVVRW0GQR1XS
ETK-1 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTN7LkCyNkDPxE1? MoO3V2FPT0WU
COLO-800 M13LcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDSTnNKSzVyPUO5MlM5PjhizszN MUjTRW5ITVJ?
CAL-12T MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTN7LkWyPFEh|ryP MVvTRW5ITVJ?
ACN MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13qOGlEPTB;NECuOFkyOSEQvF2= Mn\tV2FPT0WU
SJSA-1 M2HZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHtTWM2OD12MT6xOVk3KM7:TR?= MV\TRW5ITVJ?
PSN1 M4Kw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvHV3BKSzVyPUSxMlE4PDlizszN MVnTRW5ITVJ?
D-566MG NYPUNZpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTRzLkKwPFYh|ryP NHrpSXpUSU6JRWK=
EGI-1 NEXaV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X6NmlEPTB;NEKuOFI5KM7:TR?= NVHZcIxXW0GQR1XS
A204 NXi1dHFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:xbmlEPTB;NEKuOlM5QCEQvF2= NWLjUmQ4W0GQR1XS
Saos-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTR{LkizOlkh|ryP NIfDbnFUSU6JRWK=
SNU-C2B MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfjXmhKSzVyPUSzMlY5PzhizszN M3H5fXNCVkeHUh?=
HLE M{XaZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTR2LkC4OVYh|ryP MmLDV2FPT0WU
SW1463 NYTQTHRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR2Lkm5O|Eh|ryP MX7TRW5ITVJ?
DSH1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG5dVhxUUN3ME20OU4xODN|IN88US=> NHrDWpFUSU6JRWK=
MCF7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfrTWM2OD12NT61NFUyKM7:TR?= NVLsNGg5W0GQR1XS
K5 MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHUTWM2OD12NT65OFA2KM7:TR?= NWW0b|RZW0GQR1XS
NCI-H358 NEG4boFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7OZYV[UUN3ME20O{4zOTVizszN MnTvV2FPT0WU
NCI-H2030 Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfXNZlbUUN3ME20O{4zOzd2IN88US=> MknLV2FPT0WU
SW948 M1LScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTR5LkS2OEDPxE1? M2nvXXNCVkeHUh?=
BALL-1 NGfzZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzDc2pPUUN3ME20O{43OTZ6IN88US=> NWPGPIdMW0GQR1XS
TE-9 M1W4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3VTWM2OD12Nz65OVgyKM7:TR?= MmLqV2FPT0WU
SK-N-FI NInZcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD5RodbUUN3ME20PE4xOzV6IN88US=> MnrLV2FPT0WU
KALS-1 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T3[2lEPTB;NEiuNVI5QSEQvF2= MUHTRW5ITVJ?
HO-1-N-1 NFr2dpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnyNpVKSzVyPUS4Mlc1PDVizszN NHG0SHNUSU6JRWK=
NCI-H2452 NXvFfXk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\QRXZMUUN3ME20PU4yOTV{IN88US=> MkW2V2FPT0WU
OC-314 M3TYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTR7Lk[4N|Qh|ryP NEXVc5dUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]
臨床試験 ABT-263 is currently in Phase II clinical trial for the treatments of chronic lymphocytic leukemia.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Affinity determination Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.

細胞アッセイ:

[1]

細胞株 SCLC cell lines
濃度 0-1 μM
反応時間 48 hours
実験の流れ

Human tumor cell lines SCLC cell lines are maintained at 37 °C containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.

動物実験:

[1]

動物モデル C.B.-17 scid-bg or C.B.-17 scid mice
製剤 Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
投薬量 100 mg/kg/d
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download ABT-263 (Navitoclax) SDF
分子量 974.61
化学式

C47H55ClF3N5O6S3

CAS No. 923564-51-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 100 mg/mL (102.6 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-​[4-​[[2-​(4-​chlorophenyl)​-​5,​5-​dimethyl-​1-​cyclohexen-​1-​yl]​methyl]​-​1-​piperazinyl]​-​N-​[[4-​[[(1R)​-​3-​(4-​morpholinyl)​-​1-​[(phenylthio)​methyl]​propyl]​amino]​-​3-​[(trifluoromethyl)​sulfonyl]​phenyl]​sulfonyl]​-benzamide

カスタマーフィードバック (13)


Click to enlarge
Rating
Source , , J Clin Invest, 2014, 124(1): 117-28 . ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines KP cells & A549 cells
Concentrations 300、500 nM
Incubation Time 96 h
Results KP mouse and A549 cells treated with a combination of ATN-224 and ABT-263 showed an increase in cell death compared with cells treated with ATN-224 alone.

Click to enlarge
Rating
Source , , Cell Death Differ, 2015, 10.1038/cdd.2015.73. ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines NSC & Mcl-1 cells
Concentrations
Incubation Time 5 d
Results As seen with ABT-263, cells were largely resistant to compound alone but were extremely sensitive to combination with Mcl-1 silencing. In summary, the Bcl-xL inhibitors ABT-263 and WEHI-539 have an additive effect with Mcl-1 knockdown to reduce cell viabi眏Ỵ眐㠞眎膉癠 

Click to enlarge
Rating
Source Clin Cancer Res , 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescence polarization assay
Cell Lines
Concentrations 0.1-10 μmol/L
Incubation Time 4-12 h
Results To further characterize the nature of the binding of ABT-737 and ABT-263 to albumin, we used a fluorescence polarization assay.There are two main drug-binding sites on HSA: site 1 on subdomain IIA and site 2 on subdomain IIIA.Interestingly, ABT-263 displayed a markedly higher binding affinity to site 2 on HSA-III A than did ABT-737 (Fig. A). Whereas ABT-737 showed no binding to site 1, ABT-263 also bound to site 1 on HSA-IIA with an IC50 of 145 μmol/L (positive control phenylbutazone: 49 μmol/L; ref. 18; Fig. B) . These data show that ABT-263 has a higher albumin-binding capacity than does ABT-737, thus limiting the amount of free drug that is available to interact with the intended target, BCL2.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescein-dextran release assay/western blot
Cell Lines CLL cells
Concentrations 0-5 μmol/L
Incubation Time 1-2.5 h
Results One possible explanation for the reduced potency of ABT-263 compared with ABT-737 could be due to the former being inherently less potent. To investigate this possibility we compared their activities in a model biochemical system, using liposomes loaded with fluorescein-conjugated 10 kD dextran.The BCL-XL-mediated inhibition of liposome permeabilization was reversed in an a lmost identical concentration-dependent manner by both ABT-263 and ABT-737 (Fig. A). These results showed that both ABT-263 and ABT-737 targe t antiapoptotic BCL-XL with similar efficiency in this model liposome system containing only BCL2 family members but devoid of extraneous proteins. Another explanation for the lower potency of ABT-263 could be a lower plasma membrane permeability.we investigated the potential of ABT-737 and ABT-263 to induce cytochromec release from permeabilized CLL cells(Fig. B). ABT-737 was clearly more potentin inducing cytochrome c release from permeabilized cells.Taken together these results indicate that the reduced potential of ABT-263 to induce apoptosis cannot be explained solely by either differential plasma membrane permeability or by a lower potency of ABT-263 compared with ABT-737 to inhibit antiapoptotic BCL2 family members.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Mitochondrial membrane potential assay/Immunoprecipitation/electron microscopy/apoptosis assays
Cell Lines CLL cells/murine embryonic fibroblasts
Concentrations 10-100 nmol/L/0.3-30 μmol/L
Incubation Time 2-48 h
Results To gain in sight into the mechanism of ABT-263-induced cell death, we asked whether ABT-263 induced activation of apoptotic signaling pathways. ABT-263 induced a rapid cleavage of caspase-3 and loss of mitochondrial membrane potential, but was a gain less potent than ABT-737 ( Fig.A).To investigate the activity of both compounds at the level of BCL2 inhibition, we immunoprecipitated BCL2 upon drug treatment and measured the levels of BAK displaced by ABT-737 and ABT-263.BAK was shown to be associated with BCL2 (Fig. B). ABT-737 (10 or 100 nmol/L) efficiently d isplaced BAK from BCL2, whereas higher concentrations of ABT-263 (100 nmol /L) were required to induce release of BAK (Fig. B).ABT-263 (100 nmol/L) induced similar ultrastructural changes to ABT-737 (10 nmol/L), including condensed chromatin, rupture of the outer mitochondrial membrane, and loss of mitochondrial matrix d ensity (Fig. C).Finally, ABT-263-induced apoptosis was compl et ely inhibited in murine embryonic fibroblasts deficient for Bax and Bak (Fig. D), suggesting that ABT-263, like ABT-737 is a specific inhibitor of BCL2 proteins.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results In our study we identify two factors that affect the efficacy of the ABT-263: high cell density and plasma protein binding. In leukemic patients, the high circulating cell densities might contribute to the resistance of CLL cells to ABT-263 that we observed in whole blood as compared with standard cell culture (Fig. B).We also describe that the ABT-263 is extensively bound to albumin and that in the presence of albumin higher drug concentrations are required for apoptosis induction (Fig. D)

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results We compared the in vitro efficacy of two very closely related BCL2 antagon ists, ABT-737 and ABT-263. A direct comparison of the susceptibility of freshly isolated CLL cells to ABT-737 and ABT-263 in RPMI supplemented with 10% FCS revealed that both compounds induced efficient apoptosis but ABT-737 was∼4-fold more potent.

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Hoechst staining/western blot
Cell Lines LH86 cells/Huh7 cells
Concentrations 0–20 μM
Incubation Time 24 h
Results The higher dose of ABT-263 (10–20 μM) treatment for 24 h induced significant DNA fragmentation and caspase 9 or 3 cleavage activation in HCC cells, whereas lower concentrations of ABT-263 (0–2.5 μM) had no apoptotic toxicity to HCC cells. These results suggest that HCC cells are relatively resistant to low doses of ABT-263.

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining/Apoptosis assays
Cell Lines LH86 cells
Concentrations 1 μM
Incubation Time 1-6 h
Results As shown in Figure A, the combination treatment of HCC cells with ABT-263 (1 μM) and YM-155 (1μM) for up to 6 h has no effects on the expressions of either anti-apoptotic protein Bcl-xL or pro-apoptotic proteins including Bad, Bak, and Bax. However, as expected, the presence of YM-155 significantly decreased survivin protein expression (Figure B, left third lane). Co-treatment of cells with ABT-263 (1 μM) and YM-155 (1μM) induced an even greater decrease in survivin protein expression (Figure B, right two lanes) than that of YM-155 itself did. However, we indeed observed that ABT-263 single treatment for 3 h resulted in survivin increase (Figure B). To further determine survivin inhibition plays a critical role in sensitizing ABT-263 to induce apoptosis in HCC cells, we down-regulated survivin expression in HCC cells by siRNA duplexes targeted against human survivin mRNA, and then examined the expression of survivin by Western blotting (Figure C) and apoptotic events after ABT-263 treatments. The results demonstrated that ABT-263 induced significant apoptosis in the survivin siRNA-transfected cells, but not in siRNA Random-transfected (control) cells (Figure D, E, and F).

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining
Cell Lines LH86 cells
Concentrations 1-2.5 μM
Incubation Time 1-24 h
Results Treatment of cells with ABT-263 (1-2.5 μM) for 1 h could result in the increase of phosphorylated ERK (p-ERK) but not ERK (Figure A). On the other hand, as shown in Figure B, ABT-263 (1 μM) administration could result in survivin expression increase. Thus, in an attempt to know if ERK-survivin activation could protect cells against ABT-263 toxicity, cells were untreated or treated with ABT-263 (1 μM), PD98059 (50 μM), or pre-treated with PD98059 (50 μM) followed by ABT-263 (1 μM). As shown in Figure C and D, blocking ERK activation with specific inhibitor PD98059 enhanced ABT-263-indcued apoptosis in HCC cells. To further determine ERK anti-apoptotic effects on ABT-263 treated HCC cells, we knocked down ERK expression through siRNA mediated gene silencing (Figure E) and then administrated ABT-263. Similar results revealed that ERK depletion sensitized ABT-263-induced apoptosis (Figure F). These results suggest the activation of ERK-survivin may render cells to be resistant to low dose ABT-263-induced apoptosis.

Click to enlarge
Rating
Source Biochem Biophys Res Commun, 2011, 408(2), 344-9. ABT-263 (Navitoclax) purchased from Selleck
Method Flow cytometry
Cell Lines MDCKII wild type cells/MDR1 cells
Concentrations 50 nM
Incubation Time 24 h
Results MDCKII cells transfected with MDR1 showed significantly less apoptosis inducedby ABT-737 (Fig. C) and ABT-263 (Fig. D) than wild type cells.

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines Arf -null p185+ cells/ p185+ Arf-/- cells
Concentrations 0-1000nM
Incubation Time 24 h
Results As the navitoclax dose increased the amount of BCL-2 and BCL-X L immunoprecipitating with BIM decreased and there was a corresponding increase in MCL-1 protein associated with BIM (Fig. B). These data indicated that navitoclax displaced BIM from BCL-2 and BCL-XL and suggests that the liberated BIM could then interact with MCL-1 (Fig. B). As the navitoclax was increased we observed potentiation of the TKIs indicating a synergistic effect of combining navitoclax and TKI treatment (Fig. E&F).

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines OP-1 Ph+ B-ALL cells/TOM1 Ph+ B-ALL cells/BV173 Ph+CML cells
Concentrations 0-60 nM
Incubation Time 24 h
Results As navitoclax was increased in the cultures we observed a potentiation of the TKIs to induce apoptosis. These data indicate that like our bservations in mouse BCR-ABL cell lines, combining TKIs and navitoclax in human Ph+ cell lines can also lead to enhanced activity. While MCL-1 expression is most overtly decreased in response to TKI treatment, it is possible that combining TKI and navitoclax may effect targets other than MCL-1 leading to cell death. These data suggest that combining TKIs and navitoclax may be effective in treating human Ph+ leukemia.

文献中の引用 (36)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Bcl-2 阻害剤

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Kiof < 0.010 nM.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737は、Bcl-xL、Bcl-2とBcl-wのBH3模倣の阻害剤で、EC50 がそれぞれ78.7 nM、30.3 nM 、197.8 nMになる。

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)は Bcl-2 を抑制して、 Kiが0.22 μMになる.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37は、組み換え型Bcl-2(Bcl-xLとMcl-1)への新しい非ペプチド阻害剤で、Ki がそれぞれ 0.29 μM、1.11 μM、0.26 μMです。

  • Sabutoclax

    Sabutoclax is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT-101は、反アポトーシスのBcl-2 の強力な阻害剤であることを知られて、模倣のBH3家族です。

最近チェックしたアイテム

Tags: ABT-263 (Navitoclax)を買う | ABT-263 (Navitoclax)供給者 | ABT-263 (Navitoclax)を購入する | ABT-263 (Navitoclax)費用 | ABT-263 (Navitoclax)生産者 | オーダーABT-263 (Navitoclax) | ABT-263 (Navitoclax)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ